Bariatric–metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis

Sara Mahgoub; Philip N. Newsome

doi:10.1016/S0140-6736(23)00773-0

Bariatric–metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	1747-1749
Number of pages	3
Journal	The Lancet
Volume	401
Issue number	10390
Early online date	21 Apr 2023
DOIs	https://doi.org/10.1016/S0140-6736(23)00773-0
Publication status	Published - 27 May 2023

Bibliographical note

Acknowledgments:
PNN reports grant or research support from Novo Nordisk; and consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GSK, Intercept, Madrigal, Novo Nordisk, Pfizer, and Sun Pharma, on behalf of the University of Birmingham, Birmingham, UK, unrelated to this Comment. PNN was supported by the Birmingham National Institute for Health and Care Research (NIHR) Biomedical Research Centre. The views expressed in this Comment are informed by independent research supported in part by NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (BRC-1215-20009). The views expressed are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. SM declares no competing interests.

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(23)00773-0Licence: None: All rights reserved

Cite this

@article{227fb7dd8aa4429a841698a9286d7aa8,

title = "Bariatric–metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis",

author = "Sara Mahgoub and Newsome, {Philip N.}",

note = "Acknowledgments: PNN reports grant or research support from Novo Nordisk; and consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GSK, Intercept, Madrigal, Novo Nordisk, Pfizer, and Sun Pharma, on behalf of the University of Birmingham, Birmingham, UK, unrelated to this Comment. PNN was supported by the Birmingham National Institute for Health and Care Research (NIHR) Biomedical Research Centre. The views expressed in this Comment are informed by independent research supported in part by NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (BRC-1215-20009). The views expressed are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. SM declares no competing interests.",

year = "2023",

month = may,

day = "27",

doi = "10.1016/S0140-6736(23)00773-0",

language = "English",

volume = "401",

pages = "1747--1749",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10390",

}

TY - JOUR

T1 - Bariatric–metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis

AU - Mahgoub, Sara

AU - Newsome, Philip N.

N1 - Acknowledgments: PNN reports grant or research support from Novo Nordisk; and consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GSK, Intercept, Madrigal, Novo Nordisk, Pfizer, and Sun Pharma, on behalf of the University of Birmingham, Birmingham, UK, unrelated to this Comment. PNN was supported by the Birmingham National Institute for Health and Care Research (NIHR) Biomedical Research Centre. The views expressed in this Comment are informed by independent research supported in part by NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (BRC-1215-20009). The views expressed are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. SM declares no competing interests.

PY - 2023/5/27

Y1 - 2023/5/27

UR - http://www.scopus.com/inward/record.url?scp=85159373164&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(23)00773-0

DO - 10.1016/S0140-6736(23)00773-0

M3 - Comment/debate

C2 - 37088095

AN - SCOPUS:85159373164

SN - 0140-6736

VL - 401

SP - 1747

EP - 1749

JO - The Lancet

JF - The Lancet

IS - 10390

ER -